The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF). This is the first new therapy in more than 10 years to be approved for ...

Please provide your email address to receive an email when new articles are posted on . The FDA based nerandomilast’s approval on results from two trials, one of which was the FIBRONEER-IPF trial.

Jascayd is the first new IPF therapy approved in over 10 years, addressing a rare and serious disease with limited treatments. FDA approval was based on Phase III trials showing reduced FVC decline ...

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...

Home-based pulmonary rehabilitation has been slowly gaining momentum for chronic obstructive pulmonary disease (COPD), but access is still a challenge. "The science shows that there is greater benefit ...

Dear Doctors: I’ve been getting dizzy when I exercise or even stand up too fast. I got sent to a cardiologist who says it’s mitral valve stenosis. He thinks I’m a good candidate for a catheter repair ...

Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within ...

This summer I wrote an article about my experience with a postsurgical pulmonary embolism, hoping that sharing my story would help others take their own medical warning signs seriously. Hundreds of ...

NATICK, Mass., Sept. 16, 2025 /PRNewswire/ -- AllRock Bio Inc., a clinical-stage biotechnology company focused on advancing therapies for cardiopulmonary and fibrotic diseases, today announced a $50 ...